Omalizumab and the World Health Organization. It is also used to treat people 12 years and above with chronic spontaneous urticaria (also called chronic idiopathic urticaria), which cannot be treated with elevated doses of H1-antihistamines. The main adverse effect is anaphylaxis (a life-threatening systemic allergic reaction), with a rate of occurrence of 1 to 2 patients per 1,000. Like other protein and antibody drugs, omalizumab also causes anaphylaxis, although at a relatively low frequency among antibody drugs. The allergic reaction is probably not due to the binding characteristics of the antibody drug, but to the protein nature of the antibody. The
Basic life support is advised, although this is only effective for about 5 minutes. The term BLS is also used in some non-English speaking countries (e.g. in Italy) for the education of first responders. Basic life support Basic life support (BLS) is a level of medical care which is used for victims of life-threatening illnesses or injuries until they can be given full medical care at a hospital. It can be provided by trained medical personnel, including emergency medical technicians, paramedics, and by qualified bystanders. Many countries have guidelines on how to provide basic life support (BLS) which are formulated by professional medical